Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 2/20 | 0.61 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.45 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8336716 | 0.81 | CA2 (0.62) | TGM2CA12CA1CA2CA9 | |
| SCHEMBL11143174 | 0.80 | TGM2 (0.66) | TGM2TEAD4GSTO1CA12CA1 | |
| SCHEMBL94878 | 0.78 | TGM2 (0.68) | TGM2TEAD4GSTO1CA12CA1 | |
| SCHEMBL9179590 | 0.76 | TGM2 (0.59) | TGM2TEAD4CA1CA2MAPK1 | |
| SCHEMBL11348254 | 0.76 | TGM2 (0.59) | TGM2TEAD4GSTO1CA12CA1 | |
| SCHEMBL1424434 | 0.75 | TGM2 (0.64) | TGM2TEAD4GSTO1CA12CA1 | |
| SCHEMBL11335118 | 0.73 | TGM2 (0.61) | TGM2TEAD4GSTO1CA1CA2 | |
| SCHEMBL25667539 | 0.72 | ENPP2 (0.54) | TGM2ATMCA12CA1CA2 | |
| SCHEMBL3634388 | 0.72 | KMT2A (0.59) | TGM2TEAD4CA12CA1CA2 | |
| SCHEMBL3782892 | 0.72 | TGM2 (0.59) | TGM2TEAD4GSTO1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7348341-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2008-03-25 | — | — | US | disclosed |
| US-20030166652-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2003-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166652-A1 | Chemical compounds | CCR3, CCR1, CCR4 | TGM2 2594/4885ATM 2486/4885TEAD4 280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.